Cargando…

Postoperative Chemoradiotherapy Combined with Epirubicin-Based Triplet Chemotherapy for Locally Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction

BACKGROUND: Due to low tolerance to chemotherapy, the maximum number of cycles of postoperative adjuvant chemotherapy is 4 in adjuvant gastric clinical trials. The aim of this study is to retrospectively evaluate the safety and efficacy of adjuvant epirubicin-based triplet chemotherapy and radiother...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Guichao, Zhang, Zhen, Ma, Xuejun, Zhu, Ji, Cai, Gang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556031/ https://www.ncbi.nlm.nih.gov/pubmed/23372688 http://dx.doi.org/10.1371/journal.pone.0054233

Ejemplares similares

The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junction
por: Tang, Zhaoqing, et al.
Publicado: (2022)

Treatment for metastatic adenocarcinoma of the stomach and gastroesophageal junction: 2020
por: Hsu, Andrew, et al.
Publicado: (2020)

Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
por: Anderegg, M. C. J., et al.
Publicado: (2017)

Neoadjuvant Chemoradiotherapy versus Chemotherapy for Gastroesophageal Junction Adenocarcinoma; Which Is the Optimal Treatment Option?
por: Zandirad, Eric, et al.
Publicado: (2022)

Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, Luigi, et al.
Publicado: (2009)

Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction
por: Zhao, Qun, et al.
Publicado: (2015)

Modified Epirubicin, cisplatin, and 5-FU regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A Phase II study
por: Babu, K. Govind, et al.
Publicado: (2019)

Adjuvant chemoradiotherapy vs adjuvant chemotherapy in locally advanced Siewert type II/III adenocarcinoma of gastroesophageal junction after D2/R0 resection
por: Kang, Wen-Zhe, et al.
Publicado: (2022)

Preoperative Chemoradiotherapy for Gastroesophageal Junction Adenocarcinoma Modified by PET/CT: Results of Virtual Planning Study
por: Slavik, Marek, et al.
Publicado: (2021)

Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia
por: Jeromen, Ana, et al.
Publicado: (2012)

Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction
por: Mingol, Fernando, et al.
Publicado: (2015)

Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction
por: Li, Shoumiao, et al.
Publicado: (2017)

Effectiveness and Safety of Apatinib in Patients with Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction: A Prospective Observation Study
por: Shen, Bo, et al.
Publicado: (2020)

Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial
por: Wei, Jia, et al.
Publicado: (2023)

Individual Participant Data Network Meta-Analysis of Neoadjuvant Chemotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Junction Carcinoma
por: Faron, Matthieu, et al.
Publicado: (2023)

Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy
por: Ballhausen, Alexej, et al.
Publicado: (2022)

Gastroesophageal junction adenocarcinoma metastasizing to gingiva
por: Masamatti, Smita S, et al.
Publicado: (2013)

Epidemiology of Gastroesophageal Junction Adenocarcinoma in Korea
por: Kim, Jin-Jo
Publicado: (2018)

Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma
por: Lu, Bin, et al.
Publicado: (2019)

Systemic chemotherapy for gastro-oesophagogastric junction adenocarcinoma and stomach adenocarcinoma in a metastatic setting
por: Sanjeevaiah, Aravind, et al.
Publicado: (2020)

Fever of Undetermined Origin During Neoadjuvant Chemoradiotherapy of Gastroesophageal Junction Adenocarcinoma Due to Radiation-induced Liver Disease
por: Bashir, Babar, et al.
Publicado: (2019)

Preoperative Chemoradiotherapy Versus Postoperative Chemoradiotherapy for Patients With Locally Advanced Gastric Cancer: A Retrospective Study Based on Propensity Score Analyses
por: Yang, Wang, et al.
Publicado: (2020)

Incidence of Microscopically Positive Proximal Margins in Adenocarcinoma of the Gastroesophageal Junction
por: Gao, Fei, et al.
Publicado: (2014)

Independent Stage Classification for Gastroesophageal Junction Adenocarcinoma
por: Hirata, Yuki, et al.
Publicado: (2023)

A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma
por: Starling, N, et al.
Publicado: (2009)

Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials
por: Zhao, Xin, et al.
Publicado: (2018)

Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial
por: Tang, Zhaoqing, et al.
Publicado: (2022)

Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2‐Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
por: Al‐Batran, Salah‐Eddin, et al.
Publicado: (2020)

Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
por: Tian, Yuan, et al.
Publicado: (2021)

Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort
por: Manfredi, Sylvain, et al.
Publicado: (2022)

Dose-escalated neoadjuvant chemoradiotherapy for locally advanced oesophageal or oesophagogastric junctional adenocarcinoma
por: Duque-Santana, Victor, et al.
Publicado: (2022)

Transhiatal esophagectomy as a treatment for locally advanced adenocarcinoma of the gastroesophageal junction: postoperative and oncologic results of a single-center cohort: THE for locally advanced GEJC
por: Meillat, Hélène, et al.
Publicado: (2022)

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
por: Gil-Delgado, Maria Angeles, et al.
Publicado: (2018)

Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States †
por: Kim, Bradford J., et al.
Publicado: (2020)

Adenocarcinoma of the Gastroesophageal Junction Masquerading as Mallory-Weiss Syndrome
por: Okamoto, Takeshi, et al.
Publicado: (2022)

Mediastinal Lymph Node Dissection in Gastroesophageal Junction Adenocarcinoma
por: Kim, Jin-Jo
Publicado: (2023)

Radiotherapy for tumors of the stomach and gastroesophageal junction – a review of its role in multimodal therapy
por: Buergy, Daniel, et al.
Publicado: (2012)

The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis
por: Wang, Tongya, et al.
Publicado: (2022)

Comparison of Perioperative Chemotherapy versus Postoperative Chemoradiotherapy for Operable Stomach Cancer: A Western Canadian Province Experience
por: Zaidi, Adnan, et al.
Publicado: (2021)

Prognostic impact of sarcopenia in patients with locally advanced adenocarcinoma of the esophagogastric junction treated with neoadjuvant chemoradiotherapy
por: Ming, Jiao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3kjbblii1vmnr0f4rlsdqvncnn